Ads
related to: vascular dementia and alzheimer's combination drugs examples list
Search results
Results from the WOW.Com Content Network
Not only that, they had a 52 percent lower risk of vascular dementia, and a 39 percent lower risk of Alzheimer’s dementia. People who took SGLT-2 inhibitors for longer periods of time seemed to ...
They found that combinations of antihypertensives and combinations of one antihypertensive or more with a diuretic were associated with a lower risk for dementia. Combining lipid-lowering drugs ...
Vascular dementia is the second-most-common form of dementia after Alzheimer's disease in older adults. [4] The prevalence of the illness is 1.5% in Western countries and approximately 2.2% in Japan. It accounts for 50% of all dementias in Japan, 20% to 40% in Europe and 15% in Latin America. 25% of people with stroke develop new-onset dementia ...
Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. [1] It contains memantine, as the hydrochloride, a NMDA receptor antagonist; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor. [1] It is taken by mouth. [1]
Donepezil has been tested in other cognitive disorders, including Lewy body dementia, [33] and vascular dementia, [34] but it is not currently approved for these indications. Donepezil has also been found to improve sleep apnea in people with Alzheimer's. [35] It also improves gait in people with mild Alzheimer's. [36]
When the scientists looked at dementia subtypes, they found that SGLT-2 inhibitors were linked to 52% lower risk of vascular dementia, and 39% lower risk of Alzheimer’s disease.
Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk of dementia, overall, and of Alzheimer's disease and Parkinson's, in ...
[8] [12] Memantine was first studied in the treatment of Alzheimer's disease in 1986. [13] [14] The drug was first marketed for dementia in 1989 in Germany under the name Axura. [8] [14] [12] It was not discovered to act as an NMDA receptor antagonist until 1989, after clinical trials had initiated.
Ads
related to: vascular dementia and alzheimer's combination drugs examples list